These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 16221071)

  • 1. Dendritic cells: tools and targets for antitumor vaccination.
    den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
    Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of dendritic cells for cancer vaccination.
    Esche C; Shurin MR; Lotze MT
    Curr Opin Mol Ther; 1999 Feb; 1(1):72-81. PubMed ID: 11249687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination.
    Liu G; Black KL; Yu JS
    Expert Rev Vaccines; 2006 Apr; 5(2):233-47. PubMed ID: 16608423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC-based cancer vaccines.
    Gilboa E
    J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based vaccination against cancer.
    Saito H; Frleta D; Dubsky P; Palucka AK
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):689-710. PubMed ID: 16762730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccination for cancer therapy.
    Nestle FO
    Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human dendritic cells: natural adjuvants in antitumor immunotherapy.
    Di Nicola M; Anichini A; Mortarini R; Bregni M; Parmiani G; Gianni AM
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):265-73. PubMed ID: 10068060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells as therapeutic vaccines against cancer.
    Banchereau J; Palucka AK
    Nat Rev Immunol; 2005 Apr; 5(4):296-306. PubMed ID: 15803149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells: limited potential in immunotherapy.
    Soruri A; Zwirner J
    Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of dendritic cells in cancer immunotherapy.
    Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune response to breast cancer, and the case for DC immunotherapy.
    Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
    Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.
    Mossoba ME; Medin JA
    Expert Rev Vaccines; 2006 Oct; 5(5):717-32. PubMed ID: 17181444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.